Search research articles
Contact Us
Filters
Showing results (121-130 of 181) with videos related to
Page
of 19
Sort By:
Journal for Immunotherapy of Cancer
|
September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Advances in Therapy
|
July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
Renata Ferrarotto, Luana G Sousa, Yun Qing, et al.
JCO Precision Oncology
|
July 12, 2021
Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal Cancer
Jason T Henry, Oluwadara Coker, Saikat Chowdhury, et al.
British Journal of Cancer
|
September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H Voss, Michael S Gordon, Monica Mita, et al.
Cancer Discovery
|
February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
The Oncologist
|
February 8, 2024
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Natalie Y L Ngoi, Tin-Yun Tang, Catia F Gaspar, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 181) with videos related to
Sort By:
Page
of 19
Journal for Immunotherapy of Cancer
|
September 20, 2019
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, et al.
Advances in Therapy
|
July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
Renata Ferrarotto, Luana G Sousa, Yun Qing, et al.
JCO Precision Oncology
|
July 12, 2021
Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup>-Mutant Colorectal Cancer
Jason T Henry, Oluwadara Coker, Saikat Chowdhury, et al.
British Journal of Cancer
|
September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H Voss, Michael S Gordon, Monica Mita, et al.
Cancer Discovery
|
February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts
Timothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
JCO Precision Oncology
|
September 14, 2020
Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Ecaterina E Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.
NPJ Precision Oncology
|
April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
Omar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
The Oncologist
|
February 8, 2024
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Natalie Y L Ngoi, Tin-Yun Tang, Catia F Gaspar, et al.
Page
of 19